Join the Wegovy group to help and get support from people like you.
Wegovy News
Triple Dose Of Ozempic Safe, More Effective For Weight Loss
TUESDAY, Sept. 16, 2025 — A triple-sized weekly dose of Ozempic works better to help people with obesity shed excess pounds without significant side effects, new clinical trial results show. Obese f...
Half Discontinue Semaglutide for Weight Loss Within One Year
TUESDAY, Sept. 16, 2025 – Half of adults who start semaglutide for weight loss discontinue within a year, according to a study presented at the annual meeting of the European Association for the...
Half Of Ozempic Weight-Loss Users Drop The Drug Within A Year
MONDAY, Sept. 15, 2025 — Half of people who start taking the GLP-1 weight-loss drug Ozempic drop it within a year, a new study says. About 52% of people in Denmark prescribed semaglutide (Ozempic, W...
WHO Updates List of Essential Medicines to Include GLP-1s
TUESDAY, Sept. 9, 2025 – The World Health Organization published updated editions of its Model List of Essential Medicines (EML) and Essential Medicines for Children (EMLc) to include new treatments...
FDA Creates 'Green List' of GLP-1 Drug Ingredients Approved for Entry in the U.S.
FRIDAY, Sept. 5, 2025 -- The U.S. Food and Drug Administration has created a "green list" import alert to stop unapproved and unverified glucagon-like peptide 1 (GLP-1) drug ingredients from entering ...
14 Percent of U.S. Adults Initiate GLP-1 Receptor Agonist After Bariatric Surgery
WEDNESDAY, Sept. 3, 2025 – Fourteen percent of individuals initiate glucagon-like peptide 1 receptor agonists (GLP-1 RAs) after bariatric surgery, according to a study published online Aug. 27 in...
Wegovy Linked To Lower Heart Risks Than Similar Drugs, Study Shows
WEDNESDAY, Sept. 3, 2025 — The weight-loss drug Wegovy may lower the risk of heart attack, stroke or death more than similar medications, according to new research from its maker, Novo Nordisk. In a s...
GLP-1 Receptor Agonists Linked to Reduced Risk for Developing Uveitis
TUESDAY, Sept. 2, 2025 – Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduction in the risk for developing uveitis, according to a study published online Aug. 28 in...
Environmental Benefit Seen With GLP-1 Receptor Agonist Use in Heart Failure
FRIDAY, Aug. 29, 2025 – Patients with heart failure using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have less carbon dioxide equivalent (CO2e) greenhouse gas (GHG) emissions per patient...
GLP-1 Receptor Agonist Use Linked to Reduced Overall Risk for Cancer in Adults With Obesity
TUESDAY, Aug. 26, 2025 – For adults with obesity, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced overall risk for cancer, including lower risks for endometrial,...
FDA Approves Wegovy to Treat Serious Liver Disease
WEDNESDAY, Aug. 20, 2025 — The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk’s popular weight-loss drug Wegovy to treat a serious form of fatty liver disease. The approval makes We...
Semaglutide Not Linked to Increased Risk of Eye Disorders, Diabetic Retinopathy
MONDAY, Aug. 18, 2025 – For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy, according to a review published online Aug. 14...
Wegovy Granted Accelerated Approval in the US for the Treatment of MASH
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy (semaglutide 2.4 mg) based on a supp...
26.5 Percent of Adults With Diabetes Used GLP-1 RA Injectables in 2024
THURSDAY, Aug. 14, 2025 – In 2024, 26.5 percent of adults with diagnosed diabetes used glucagon-like peptide 1 receptor agonist (GLP-1 RA) injectables, according to an August data brief published by...
GLP-1 Receptor Agonists May Reduce Complications of Diabetic Retinopathy
TUESDAY, Aug. 12, 2025 – For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Cardiovascular Risk Reduction, Nonalcoholic Fatty Liver Disease